GLP-1 Medications in Addiction Treatment

A New Tool in Addiction Medicine

GLP-1 receptor agonists — medications like semaglutide, liraglutide, and tirzepatide, developed originally for diabetes and obesity — are emerging as one of the most significant developments in addiction medicine in years. A growing body of research, including large-scale clinical studies, indicates that these medications reduce craving and substance use across multiple classes of addiction: alcohol, opioids, stimulants, nicotine, and cannabis. This is not a theoretical finding. It is being observed in clinical practice now, and I use these medications in my work.

How They Work

GLP-1 is a hormone produced in the gut and in a small population of neurons in the brainstem. Its receptors are expressed not only in the pancreas and gastrointestinal tract but in brain regions central to the neurobiology of addiction: the ventral tegmental area, the nucleus accumbens, and the prefrontal cortex. These are the core structures of the mesolimbic dopamine reward pathway — the circuitry that drives craving, compulsive use, and the inability to stop despite consequences.

GLP-1 receptor agonists, by acting on these receptors, modulate dopamine signaling in ways that appear to reduce the intensity of craving itself — not against any single substance specifically, but against the reward-seeking drive that underlies addiction broadly. Patients describe this as a quieting: the constant preoccupation with the substance (or the behavior) loses its urgency. The pull is still there, but it is no longer overwhelming. The capacity to choose — genuinely choose, rather than fight a losing battle against neurological compulsion — begins to return.

What the Evidence Shows

The evidence base is developing rapidly. Large epidemiological studies involving hundreds of thousands of patients have found that GLP-1 medication use is associated with significant reductions in the risk of developing substance use disorders across every major substance class — alcohol, opioids, cocaine, cannabis, and nicotine. Among people with existing substance use disorders, GLP-1 use has been associated with substantial reductions in emergency department visits, hospitalizations, overdoses, and drug-related deaths.

Clinical trials are now underway specifically examining GLP-1 medications in the treatment of alcohol use disorder, opioid use disorder, cocaine use disorder, and others. Preliminary results have been encouraging, including reductions in alcohol consumption, reduced opioid craving, and extended periods of abstinence. This is a rapidly evolving area of research, and the picture will become clearer over the next few years. What is already clear is that these medications are doing something meaningful to the neurobiology of craving.

How I Use Them

I prescribe GLP-1 medications in my practice as one tool among several — not as a replacement for the broader work of treatment, but as a way of creating neurological conditions that make that work more possible. The parallel to other medications I use is direct: Suboxone stabilizes the opioid system so a person can think clearly and engage in treatment; a benzodiazepine taper restabilizes the GABA system; GLP-1 medications appear to modulate the reward system in a way that reduces the compulsive drive that makes addiction so difficult to interrupt.

The medication does not do the work. It creates conditions under which the work — the ongoing conversation about what has been driving the addiction, what the substance or behavior has been managing, what has never been examined — becomes accessible. That has always been the role of medication in this practice.

I use GLP-1 medications most directly in the treatment of compulsive overeating and obesity, where the evidence is most established and the FDA indications are clearest. I also consider them in the treatment of alcohol and other substance use disorders where craving remains a significant clinical problem despite other interventions, and where the emerging evidence supports their use. As with all medication decisions, this is individualized.

An Evolving Field

The science connecting GLP-1 receptor signaling to addiction neurobiology is still developing. What makes it compelling is the convergence of multiple lines of evidence — preclinical research, large-scale epidemiological data, early clinical trials, and the consistent clinical experience of reduced craving across substance classes. This is not a fad or a repurposed diet drug. It is a pharmacological intervention that acts directly on the neural circuitry of addiction.

I follow this research closely and am pursuing additional training in obesity medicine to deepen my work in this area. As the evidence base grows, the role of GLP-1 medications in addiction treatment will become more defined. What is already clear is that they represent a genuinely new tool — and in a field where the available tools have been limited for decades, that matters.

Getting in Touch

The first conversation is free and completely confidential. There is no obligation of any kind.

Call directly: (646) 418-7077